Nicolaes GA, Dahlbäck B (February 2003). "Congenital and acquired activated protein C resistance". Seminars in Vascular Medicine. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID15199491. S2CID260369702.
Eichacker PQ, Natanson C, Danner RL (October 2006). "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly". The New England Journal of Medicine. 355 (16): 1640–2. doi:10.1056/NEJMp068197. PMID17050887.
Kisiel W, Ericsson LH, Davie EW (November 1976). "Proteolytic activation of protein C from bovine plasma". Biochemistry. 15 (22): 4893–900. doi:10.1021/bi00667a022. PMID990250.
Kisiel W, Canfield WM, Ericsson LH, Davie EW (December 1977). "Anticoagulant properties of bovine plasma protein C following activation by thrombin". Biochemistry. 16 (26): 5824–31. doi:10.1021/bi00645a029. PMID588557.
Vehar GA, Davie EW (February 1980). "Preparation and properties of bovine factor VIII (antihemophilic factor)". Biochemistry. 19 (3): 401–10. doi:10.1021/bi00544a001. PMID7356933.
Wildhagen KC, Lutgens E, Loubele ST, ten Cate H, Nicolaes GA (December 2011). "The structure-function relationship of activated protein C. Lessons from natural and engineered mutations". Thrombosis and Haemostasis. 106 (6): 1034–45. doi:10.1160/TH11-08-0522. PMID22072231. S2CID3060393.
España F, Berrettini M, Griffin JH (August 1989). "Purification and characterization of plasma protein C inhibitor". Thrombosis Research. 55 (3): 369–84. doi:10.1016/0049-3848(89)90069-8. PMID2551064.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (June 2008). "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 160S–198S. doi:10.1378/chest.08-0670. PMID18574265.
Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF (14 March 2012). Martí-Carvajal AJ (ed.). "Human recombinant activated protein C for severe sepsis". The Cochrane Database of Systematic Reviews (3): CD004388. doi:10.1002/14651858.CD004388.pub5. PMID22419295.
Griffin JH, Fernández JA, Mosnier LO, Liu D, Cheng T, Guo H, Zlokovic BV (2006). "The promise of protein C". Blood Cells, Molecules & Diseases. 36 (2): 211–6. doi:10.1016/j.bcmd.2005.12.023. PMID16464623.
Nicolaes GA, Dahlbäck B (February 2003). "Congenital and acquired activated protein C resistance". Seminars in Vascular Medicine. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID15199491. S2CID260369702.
Eichacker PQ, Natanson C, Danner RL (October 2006). "Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly". The New England Journal of Medicine. 355 (16): 1640–2. doi:10.1056/NEJMp068197. PMID17050887.
Mammen EF, Thomas WR, Seegers WH (December 1960). "Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A)". Thrombosis et Diathesis Haemorrhagica. 5: 218–49. PMID13765990.
Kisiel W, Ericsson LH, Davie EW (November 1976). "Proteolytic activation of protein C from bovine plasma". Biochemistry. 15 (22): 4893–900. doi:10.1021/bi00667a022. PMID990250.
Kisiel W, Canfield WM, Ericsson LH, Davie EW (December 1977). "Anticoagulant properties of bovine plasma protein C following activation by thrombin". Biochemistry. 16 (26): 5824–31. doi:10.1021/bi00645a029. PMID588557.
Vehar GA, Davie EW (February 1980). "Preparation and properties of bovine factor VIII (antihemophilic factor)". Biochemistry. 19 (3): 401–10. doi:10.1021/bi00544a001. PMID7356933.
Wildhagen KC, Lutgens E, Loubele ST, ten Cate H, Nicolaes GA (December 2011). "The structure-function relationship of activated protein C. Lessons from natural and engineered mutations". Thrombosis and Haemostasis. 106 (6): 1034–45. doi:10.1160/TH11-08-0522. PMID22072231. S2CID3060393.
España F, Berrettini M, Griffin JH (August 1989). "Purification and characterization of plasma protein C inhibitor". Thrombosis Research. 55 (3): 369–84. doi:10.1016/0049-3848(89)90069-8. PMID2551064.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (June 2008). "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 160S–198S. doi:10.1378/chest.08-0670. PMID18574265.
Martí-Carvajal AJ, Solà I, Lathyris D, Cardona AF (14 March 2012). Martí-Carvajal AJ (ed.). "Human recombinant activated protein C for severe sepsis". The Cochrane Database of Systematic Reviews (3): CD004388. doi:10.1002/14651858.CD004388.pub5. PMID22419295.
Griffin JH, Fernández JA, Mosnier LO, Liu D, Cheng T, Guo H, Zlokovic BV (2006). "The promise of protein C". Blood Cells, Molecules & Diseases. 36 (2): 211–6. doi:10.1016/j.bcmd.2005.12.023. PMID16464623.
Nicolaes GA, Dahlbäck B (February 2003). "Congenital and acquired activated protein C resistance". Seminars in Vascular Medicine. 3 (1): 33–46. doi:10.1055/s-2003-38331. PMID15199491. S2CID260369702.
Wildhagen KC, Lutgens E, Loubele ST, ten Cate H, Nicolaes GA (December 2011). "The structure-function relationship of activated protein C. Lessons from natural and engineered mutations". Thrombosis and Haemostasis. 106 (6): 1034–45. doi:10.1160/TH11-08-0522. PMID22072231. S2CID3060393.